David Bear, DO
Neurology · Pensacola, FLNPI 1689643645
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $394,980 of the $512,796 with a category attached, or 77.0%. 60 manufacturers reported payments, led by Lilly USA, LLC at 47.9% of the total. 2025 is the largest year on record at $139,462, 3.3 times the $42,673 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,116 payments — averaging $242.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$246K
- AbbVie$89K
- Lundbeck LLC$30K
- Teva Pharmaceuticals USA, Inc.$24K
- Eli Lilly$17K
- Impel Pharmaceuticals Inc.$16K
- plus $90K from 54 others
Across 124 payments — averaging $78,511 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.5M
- Novartis$2M
- Sage Therapeutics, LLC$110K
- E.r. Squibb & Sons, L.L.C.$95K
- Ipsen Innovation$31K
- Amgen$27K
What the payments were for
- Consulting fees$67,35413%
- Speaking & faculty fees$394,98077%
- Grants$440%
- Travel & lodging$14,4503%
- Food & beverage$35,4197%
- Education$5490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$512,796 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 66 | $426,929 |
| XywavSodium,calcium,mag,pot Oxybate | 20 | $388,687 |
| XyremSodium Oxybate | 17 | $329,661 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 32 | $290,614 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 34 | $285,470 |
| QuliptaAtogepant | 125 | $162,233 |
| CopaxoneGlatiramer Acetate | 18 | $148,668 |
| GilenyaFingolimod Hcl | 14 | $147,494 |
| Nurtec OdtRimegepant Sulfate | 93 | $144,018 |
| NuplazidPimavanserin Tartrate | 25 | $134,607 |
| Emgality PenGalcanezumab-Gnlm | 155 | $128,451 |
| TysabriNatalizumab | 13 | $114,384 |
| XcopriCenobamate | 89 | $113,703 |
| EpidiolexCannabidiol (Cbd) | 31 | $109,536 |
| UbrelvyUbrogepant | 94 | $94,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Zavzpret | $14,328 | $450,449140 claims |
| Grifols USA, LLCGamunex-C | $228 | $426,92966 claims |
| AbbVieQulipta, Ubrelvy, Botox | $89,294 | $271,915230 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $24,011 | $148,66818 claims |
| NovartisGilenya | $2,548 | $147,49414 claims |
| Acadia Pharmaceuticals IncNuplazid | $344 | $134,60725 claims |
| BiogenTysabri | $807 | $114,38413 claims |
| SK Life Science, Inc.Xcopri | $1,103 | $113,70389 claims |
| UCB, Inc.Neupro, Nayzilam, Briviact | $666 | $65,16951 claims |
| Impel Pharmaceuticals Inc.Trudhesa | $15,780 | $59,63316 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $447 | $52,81340 claims |
| Amneal Pharmaceuticals LLCRytary | $179 | $29,99312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Pensacola
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.